Engineered immune cells for improved migration

Engineering T cells with a constitutively active RhoA Q63L mutant enhances their motility and tumor infiltration in dense stromal environments, addressing the challenge of immune exclusion in solid tumors and improving therapeutic efficacy.

WO2026241703A1PCT designated stage Publication Date: 2026-11-19REGENTS OF THE UNIVERSITY OF MINNESOTA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/028475
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

T cells face significant challenges in infiltrating and persisting within the dense tumor microenvironment of solid tumors, particularly pancreatic ductal adenocarcinoma (PDA), due to physical and biochemical barriers imposed by the extracellular matrix, leading to immune exclusion and reduced therapeutic efficacy.

Method used

Engineering T cells with a constitutively active RhoA Q63L mutant using CRISPR/Cas9 genome editing to enhance cytoskeletal dynamics and motility, allowing them to navigate through dense stromal environments without degrading the extracellular matrix.

Benefits of technology

RhoA Q63L mutant T cells exhibit increased motility, metabolic activity, and tumor engagement, overcoming physical barriers and improving therapeutic outcomes by enhancing infiltration and persistence within solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000022_0001
    Figure IMGF000022_0001
  • Figure IMGF000022_0002
    Figure IMGF000022_0002
  • Figure 00000033_0000
    Figure 00000033_0000
Patent Text Reader

Abstract

In one aspect, the present disclosure relates to an engineered immune cell including increased RhoA activity. In one or more embodiments, the cell includes a mutant RhoA protein, which may include a constitutively activating mutation. In one or more embodiments, the cell exhibits increased motility relative to a comparable unmodified cell. In another aspect, the present disclosure relates to a method of treating a subject including administering the engineered cell described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Provisional Patent Application Attorney Docket No. 0110.000727W001

[0002] ENGINEERED IMMUNE CELLS FOR IMPROVED MIGRATION

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Serial No. 63 / 806,346, filed on May 15, 2025, the disclosure of which is incorporated by reference herein in its entirety.

[0004] SEQUENCE LISTING

[0005] This application contains a Sequence Listing electronically submitted via Patent Center to the United States Patent and Trademark Office as an XML file entitled “0110.000727W001.xml” having a size of 4,005 bytes and created on May 15, 2026. The information contained in the Sequence Listing is incorporated by reference herein.

[0006] GOVERNMENT FUNDING

[0007] This invention was made with government support under CA254849, and CA268069 awarded by the National Institutes of Health. The government has certain rights in the invention.

[0008] SUMMARY

[0009] In one aspect, the present disclosure relates to an engineered immune cell including increased RhoA activity. In one or more embodiments, the cell includes a mutant RhoA protein. In one or more embodiments, the mutant RhoA protein includes a constitutively activating mutation. In one or more embodiments, the RhoA protein includes an amino acid sequence including a Y42C, G14V, Q63L, L57V, D59G, A61D, D76G, K18N, C16R, or A161P mutation. In one or more embodiments, the mutant RhoA protein includes a Q63L mutation. In one or more embodiments, the cell is a human cell.

[0010] In one or more embodiments, the cell exhibits increased motility relative to a comparable unmodified cell. In one or more embodiments, the cell exhibits increased solid tumor infiltration relative to a comparable unmodified cell. In one or more embodiments, the cell is a T cell or an NK cell. In one or more embodiments, the cell includes a chimeric antigen receptor (CAR), anengineered TCR, a targeting antibody, a bispecific killer cell engager (BiKE), or a trispecific killer cell engager (TriKE).

[0011] In another aspect, the present disclosure relates to a method of treating a subject including administering the engineered cell described herein. In one or more embodiments, the subject has cancer. In one or more embodiments, the subject has one or more solid tumors. In one or more embodiments, the subject has a fibrotic state. In one or more embodiments, the subject is a human.

[0012] The above summary is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the application, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

[0013] BRIEF DESCRIPTION OF THE FIGURES

[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0015] FIG. 1. Limited T cell migration in pancreatic ductal adenocarcinoma (PDA) tumor microenvironment (TME). (A) Representative time-lapse images showing T cell migration within a mouse PDA tumor slice over 8 hours (top row), and T cell migration in 3D collagen gel matrix over 1 hour (bottom row). Sample cell positions are highlighted with arrows.

[0016] FIG. 2. T cell motility and movement. (A) Quantifications of T cell motility coefficient, displacement, and track confinement ratio in tumor slice and 3D collagen gel, demonstrating a significant reduction in T cell motility in the PDA TME compared to the collagen gel. (B) Images and quantification of total area covered by T cells overtime in tumor slice over 8 hours (Left) and in 3D collagen gel over 1 hour (right).

[0017] FIG. 3. Generation and characterization of human RhoA Q63L mutant CD8+ T cell. (A) Lentiviruses encoding RQR8 control, RhoA, and RhoA Q63L mutant, driven by MND promoter were prepared. T2A and P2A encode two self-cleavage peptides. RQR8 was used for detection and purification of transduced cells. (B) Schematic diagram showing the hypothesized effect ofRhoA Q63L mutation on RhoA cycle regulation. (C) Representative flow cytometry data of purified RQR8+ T cells using PE-CD34QBend antibody.

[0018] FIG. 4. Generation and characterization of human RhoA Q63L mutant CD8+ T cell. (A) Representative Western blots of whole cell lysate and RhoA-GTP pulldown samples with RBD beads with antibodies of RhoA and P-actin. Multiple controls of lentiviruses and treatments were included to assess basal protein expression levels in T cells. (B) Representative immunofluorescence images of T cells stained with RhoA and RhoA-GTP antibodies, and counter stained with DAPI. Bar: 50 pm.

[0019] FIG. 5. Generation and characterization of human RhoA Q63L mutant CD8+ T cell. (A) Human CD8+ T cell proliferation rate and viability with and without Q63L mutation over four days. (B) Representative images of infiltration cell morphology in 3D collagen gels.

[0020] Quantification of cell morphology showed significantly decreased circularity but increased cell size in the Q63L mutant T cells compared to the control. Each dots represents an individual T cells from three replicating experiments. Data are expressed as mean ± SEM. ****P<0.0001.

[0021] FIG. 6. RhoA Q63L mutation resulted in significantly increased motility in both human and murine CD8+T cells. (A) Representative MP time-lapse images of human Q63L and control CD8+T cells in 3D collagen gels. Sample migration tracks of individual T cells are shown. Images are samples from imaging every 1 minute for at least 1 hour. (B) Quantification of the human Q63L and control CD8+T cells migration track confinement in 3D collagen gels. A confinement ratio of 0 indicates track starting and ending position is the same, while values close to 1 indicate directed migration. (C) Motility coefficient for the human Q63L and control CD8+T cells migrating within 3D collagen matrices showed significantly increased motility coefficient for the Q63L mutant T cells. Each dot represents a single cell tracked over time-lapse imaging. (D) Average area covered by T cells per frame in 3D collagen gel. N=4 biological replicates.

[0022] FIG. 7. RhoA Q63L mutation resulted in significantly increased motility in both human and murine CD8+T cells. (A) Schematic of the experimental workflow for assessing CD8+T cell migration in live mice PDA tumor slices. (B) Representative MP time-lapse images of mice RhoA Q63L and control CD8+T cells in KPCT PDA tumor slices. (C) Significantly increased motility coefficient of the mice Q63L CD8+T cells migrating within tumor slices compared to the control cells. (D) Representative Z-plane maximum intensity projection images showing the cumulative area covered by infiltrated T cells in tumor slices over a 2-hour period, regions withhigh T cell presence are outlined. Statistical tests are unpaired T test with Welch’s correction. «« p<0.0001.

[0023] FIG. 8. Effect of RhoA Q63L mutation on human CD8+T cell metabolism, cortical tension, and differentiation. (A) Fluorescence lifetime imaging of control (top row) and RhoA Q63L-modified (bottom row) CD8+T cells embedded in 3D collagen gels. Left: unstimulated; middle: stimulated with anti-CD3 / CD28 antibodies; right: stained with Flipper- TR to assess cell cortical tension. (B) Quantification of NAD(P)H al percentage in unstimulated and CD3 / CD28-stimulated control and Q63L-modified CD8+T cells. Q63L T cells showed significantly elevated baseline al levels, indicating increased glycolytic metabolism. (C) Quantification of average Z-stack fluorescence lifetimes from Flipper- TR-stained cells reveals significantly longer lifetimes in Q63L T cells, indicating an increase in cortical membrane tension.

[0024] FIG. 9. Multiparameter flow cytometry analysis of T cell subpopulations. RhoA Q63L-modified T cells displayed a higher frequency of CD8+T cells and effector subsets compared to control T cells.

[0025] FIG. 10. Effect of RhoA Q63L mutation on human CD8+T cell metabolism, cortical tension, and differentiation. (A) Percentage of CD8+T cells across differentiation stages: naive (Tn), central memory (Tcm), effector memory (Tern), and terminally differentiated effector (E) cells. RhoA Q63L-modified T cells exhibited a more differentiated phenotype, with the majority residing in the Tem3 (~60%) and E (~ 15%) subsets. (B) Expression of exhaustion markers PD-1 and LAG-3 on CD8+T cells. RhoA Q63L-modified T cells exhibited reduced PD-1 and LAG-3 expression compared to control T cells, suggesting a less exhausted phenotype.

[0026] FIG. 11. Incorporation of the RhoA Q63L mutation into mesothelin-targeting CAR-T cells enhances RhoA activity and T cell motility. (A) Schematic representation of the vector constructs for mesothelin-CAR (mesoCAR) T cells with and without the RhoA Q63L mutation. (B-C) Western blot and RhoA-GTP pulldown assays confirming that mesoCAR Q63L T cells express elevated total RhoA protein levels and increased active RhoA-GTP compared to control mesoCAR T cells.

[0027] FIG. 12. Incorporation of the RhoA Q63L mutation into mesothelin-targeting CAR-T cells enhances RhoA activity and T cell motility. (A) Migration of RhoA Q63L-modified and control mesothelin-CAR T cells in 3D collagen gels. Migration trajectories are overlaid on the time-lapse images, illustrating enhanced motility and directional movement in Q63L-modifiedCAR T cells compared to controls. Color scale bar indicates instantaneous cell speed (green: low speed; red: high speed). Quantification of the meso-CAR T cell migration in 3D collagen gel. (B) Motility coefficient. (C) Track confinement ratio. (D) Track displacement. (E) Mean track speed. RhoA Q63L-modified CAR T cells exhibit significantly improved migratory behavior across all metrics compared to controls.

[0028] FIG. 13. 2D killing quantification: mesoCAR T cells were co-cultured with AsPCl cell in 96 well-plate at different ratio and percentage of live AsPCl cells were calculated compared to the no T cell control. Both meso-CAR and meso-CAR Q63L T cells showed similar killing rates.

[0029] FIG. 14. Representative images of area covered by control, RhoA Q63L, mesoCAR, mesoCAR Q63L T cells in 3D collagen gel embedded with AsPCl cells and the corresponding cell tracks. Red: AsPCl cells; Yellow: projected total area covered by T cells over 90 minutes.

[0030] FIG. 15. Quantification of T cell motility in 3D collagen matrices. (A) Quantification of the control, RhoA Q63L, mesoCAR, mesoCAR Q63L T cells motility in 3D collagen gel. (B) Quantification of the control, RhoA Q63L, mesoCAR, mesoCAR Q63L T cells motility in 3D collagen gel embedded with AsPCl cells. (C) Quantification of T cell- AsPCl cell intervention events per T cells for the control, RhoA Q63L, mesoCAR, mesoCAR Q63L T cell groups in 3D collagen gel embedded with AsPCl cells. * P<0.05; ** P<0.01, *** P<0.001.

[0031] FIG. 16. Representative multiphoton maximum-intensity Z-proj ection images of mesoCAR and mesoCAR RhoA(Q63L) modified T cells migrating and interaction with AsPC-1 cells in 3D collagen matrices.

[0032] FIG. 17. Quantification of mesoCAR and mesoCAR RhoA(Q63L) modified T cell motility in collagen matrices with or without AsPC-1 cells. (A) Quantification of mesoCAR and mesoCAR RhoA(Q63L) modified T cell motility in 3D collagen matrices containing embedded AsPC-1 cells. (B) Quantification of mesoCAR and mesoCAR RhoA(Q63L) modified T cell motility in collagen regions lacking AsPC-1 cells.

[0033] FIG. 18. AsPC-1 cancer cells and human CAFs (1:2 ratio) embedded in 2 mg / mL collagen gels were orthopedically implanted into the pancreas of NSG mice (Day -18). Tumor progression was monitored by MRI on days -6, 0, and 8. On day 1, mice (n=4 per group) received intraperitoneal injections of mesoCAR T cells, mesoCAR Q63L modified T cells, or no T cells. FIG. 18 shows representative MRI images of days -6, 0, and 8 for each treatment group. Tumors are outlined in each group and an overlay at each timepoint is shown.FIG. 19. Tumor volume trajectories and T cell infiltration overtime. (A) Tumor volume was calculated as V= 1 (L*W2), where L is the longest diameter and W is the shortest diameter. (B) Quantified tumor volume, number of CD34+ CAR T cells, percentage of CD34+ CAR T cells among all live cells, and metastatic burden after one week of treatment.

[0034] FIG. 20. CD34 presence in tumor sections treated with mesoCAR Q63L. (A) Representative immunofluorescence images of FFPE tumor sections stained for pan-cytokeratin, CD34, and DAPI (nuclei). mesoCAR Q63L modified T cell-treated tumors showed increased intertumoral CAR t cell presence. Scale bar = 100 pm. (B) Quantification of CD34+ cell numbers per field of view in tumor immunofluorescence section. Data are presented as mean + / -s.e.m. Statistical significance was determined using one-way ANOVA with Tukey’s post hoc test. For all pairwise comparisons, unpaired two-tailed t-tests with Welch’s correction were used.

[0035] DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS Immunotherapy, which harnesses the body’s immune system to target malignancies, has revolutionized the treatment landscape for hematologic cancers, including but not limited to lymphoma, leukemia, and multiple myeloma, significantly improving patient survival. Among various immunotherapeutic strategies, CD8+T cells have potent cytotoxic capabilities. These cells recognize and eliminate tumor cells through T-cell receptor (TCR) binding to antigenic peptides presented on the surface of cancer cells.

[0036] The tumor microenvironment (TME) of cancers, particularly cancers including solid tumors, can greatly influence the delivery of therapeutics. In particular, large therapeutics such as cell therapies often exhibit poor infiltration into solid tumors where the TME is dense. One example of such a cancer is pancreatic ductal adenocarcinoma (PDA). PDA remains largely refractory to immunotherapy, at least in part due to its desmoplastic stroma, which creates both physical and biochemical barriers that restrict T cell infiltration and persistence. To remove PDA cells within a solid tumor, CD8+T cells must infiltrate the TME, migrate through stromal barriers, and directly interact with malignant cells. The dense extracellular matrix (ECM) of PDA, which includes fibroblasts, collagen, and hyaluronan, presents an effective physical barrier T cell infiltration, often leading to immune exclusion. Even when T cells can infiltrate a solid tumor, they frequently remain trapped within the peripheral stromal regions, unable to penetratethe tumor core where cancer cells reside. This spatial segregation between effector T cells and tumor cells represents a mechanism of immune resistance in PDA.

[0037] Emerging clinical and translational studies have demonstrated that higher densities of peritumoral CD8+T cells are correlated with improved overall survival in solid tumors.

[0038] However, the presence of T cells alone is insufficient. Effective anti-tumor immunity requires functional infiltration, persistent tumor engagement, and cytotoxic activity. Therefore, strategies to enhance CD8+T cell trafficking and intratumoral migration, and prolong tumor interaction are important for improving immunotherapy efficacy in solid tumors such as PDA. One potential approach is to modulate cytoskeletal dynamics, a key regulator of T cell motility, activation, and persistence. RhoA, a small GTPase, plays a role in actin remodeling, cell contractility, and migration, all of which are critical for T cell infiltration into solid tumors. Notably, RhoA activation enhances amoeboid migration, a movement strategy that enables cells to navigate confined spaces without requiring ECM degradation. Given the physical constraints imposed by the TME of solid tumors, harnessing RhoA signaling to enhance T cell motility may provide a promising approach to overcoming immune exclusion and improving tumor engagement.

[0039] In contrast to past efforts to improve tumor infiltration, the methods described herein do not target the stroma directly but rather improves the cells’ ability to navigate the dense TME. By avoiding the need to deplete or remodel stromal components, cytoskeletal engineering may offer a more universally applicable and tunable strategy to enhance T cell function without disrupting potentially protective stromal architecture.

[0040] Although transient pharmacological activation of RhoA has been shown to increase T cell speed and motility, pharmacological activation is likely insufficient to achieve a meaningful, sustained response. Rather, a sustained enhancement in migration is likely necessary to achieve persistent tumor infiltration. The present application describes the novel effects of RhoA Q63L, a constitutively active RhoA mutant that prevents GTP hydrolysis, thereby maintaining persistent activation. As is demonstrated in the examples, engineered T cells having constitutively active RhoA exhibit sustained increases in motility, allowing them to more effectively infiltrate and persist within the TME.

[0041] RhoA Q63L mutant CD8 T cells were generated using CRISPR / Cas9 genome editing and evaluated for migration potential, metabolic adaptations, differentiation status, and tumor interaction frequency. The results provided herein demonstrate that RhoA Q63L significantlyincreased total RhoA and active RhoA-GTP levels in T cells. Notably, this mutation did not affect proliferation or viability, indicating that sustained RhoA activation does not impose a metabolic burden on T cells. Functionally, RhoA Q63L T cells exhibited enhanced motility across multiple platforms, including 3D collagen matrices, tumor spheroids, and live PDA tumor slices, adopting an amoeboid migration phenotype accompanied by increased metabolic activity and cortical tension. These findings suggest that RhoA Q63L-driven cytoskeletal remodeling and metabolic adaptation facilitate enhanced T cell migration.

[0042] In addition, the RhoA Q63L mutant CD8+T cells were used to generate mesothelin-targeting chimeric antigen receptor (mesoCAR)-T cells. The RhoA Q63L mutant CAR T cells were used to test whether increased motility improved tumor engagement in a therapeutic setting. While RhoA Q63L mesoCAR T cells displayed comparable killing efficacy to control mesoCAR T cells in a 2D cytotoxicity assay, they exhibited a significantly increased interaction frequency with PDA cancer cells in 3D collagen matrices. This increased interaction suggested that enhanced migration facilitates tumor search efficiency and engagement. These findings highlight RhoA Q63L as a potent driver of T cell motility, providing a novel strategy to overcome physical barriers in the TME and improve immunotherapy outcomes.

[0043] Using live tumor slice imaging and 3D collagen matrices, this disclosure provides direct evidence that the PDA TME imposes profound biophysical barriers on T cell migration. Naive and unmodified T cells exhibited severely limited displacement and spatial confinement within ex vivo tumor slices. In contrast to unmodified T cells, RhoA Q63L-expressing T cells displayed significantly improved velocity, directional persistence, and field-of-view coverage across both collagen gels and native tumor tissue. These data support the idea that targeting cell-intrinsic migratory programs can bypass stromal exclusion, a limitation in current T cell-based approaches for PDA.

[0044] Without wishing to be bound by theory, it is thought that constitutive RhoA activation promotes a transition toward an amoeboid migration mode, characterized by elevated cortical tension and increased glycolytic metabolism. These features enhance cytoskeletal contractility and facilitate movement through tight ECM spaces without reliance on proteolytic degradation. In addition, RhoA Q63L T cells retained a differentiated effector phenotype and lacked markers of exhaustion, suggesting that enhanced cytoskeletal signaling can support T cell functional maturation and persistence.In sum, the present disclosure describes for the first time the idea that cytoskeletal engineering via constitutive RhoA activation can be used to reprogram T cells and overcome physical barriers in PDA, improving infiltration and tumor cells engagement in densely fibrotic environments. This strategy may represent a broadly applicable next-generation platform to enhance adoptive immunotherapies for solid tumors having stromal exclusion and immune suppression.

[0045] Engineered Cells

[0046] The engineered cells described herein are typically immune cells. In one or more embodiments, the engineered cell is a T cell. The T cell may be a CD4+ T cell, a CD8+ T cell, a CD4+ / CD8+ T cell, or a naive T cell. In one or more embodiments, the T cell is an a / p T cell. In one or more embodiments, the T cell is a y / 8 T cell. In one or more embodiments, the engineered cell is a natural killer (NK) cell.

[0047] In one or more embodiments, the engineered cell is isolated from peripheral blood. In one or more embodiments, an engineered cell is derived from an induced pluripotent stem cell (iPSC). In embodiments wherein the engineered cell is administered to a subject, the engineered cell may be derived from the subject’s own cells, such as peripheral blood cells, T cells, NK cells, hematopoietic stem cells (HSCs) or iPSCs. In embodiments wherein the engineered cell is administered to a subject, the engineered cell may be derived from donor cells, such as peripheral blood cells, T cells, NK cells, HSCs, or iPSCs.

[0048] An engineered cell of the present disclosure may be identified by its activity. Typically, the engineered cell described herein exhibits improved infiltration in a solid tumor. In one or more embodiments, the engineered cell exhibits increased contractile force. This may cause the engineered cell to exhibit a more circular morphology as compared to a non-mutant cell.

[0049] Morphology may be measured, for example, using microscopy as described in the Examples. In one or more embodiments, the engineered cell exhibits decreased adhesion to its environment. The engineered cell may exhibit an amoeboid phenotype. In one or more embodiments, the engineered cell exhibits increased motility as compared to a non-mutant cell. Motility may be measured, for example, using timelapse fluorescence microscopy as described in the Examples.

[0050] RhoA MutantsThe engineered cell described herein typically includes one or more mutations to a RhoA gene and / or protein. RhoA mutants are described with reference to the amino acid sequence. Any suitable genetic variant may be used to prepare a mutant protein having the amino acid sequence described herein.

[0051] Ras homolog family member A (RhoA) is a small GTPase protein encoded by the RHOA gene in humans. RhoA functions in signaling cascades within the cell that relate to man cellular functions, including cytoskeletal organization and cell cycle maintenance. Active RhoA-GTP activates downstream effectors. Following activation, GAP converts the RhoA-GTP to RhoA-GDP, reverting RhoA to its inactive form. GEF converts GDP to GTP, activating RhoA. In one or more embodiments, the mutant RhoA of the present disclosure has impaired GTP hydrolysis, resulting in increased RhoA activity.

[0052] In one or more embodiments, an engineered cell includes knockout of a GAP gene. In one or more embodiments, an engineered cell includes knockout of a GEF gene.

[0053] In one or more embodiments, a mutant RhoA protein is constitutively active. Typically, the mutant RhoA protein includes a gain of function mutation. In one or more embodiments, a mutant RhoA protein exhibits increased activity relative to a wild-type RhoA protein. In one or more embodiments, a RhoA protein is hyperconstitutively active.

[0054] In one or more embodiments, a mutant RhoA protein includes one or more mutations that impair GTP hydrolysis. The mutant RhoA protein may include one or more mutations including Y42C, G14V, Q63L, L57V, D59G, A61D, D76G, K18N, C16R, and / or A161P. Thus, in one or more embodiments, a mutant RhoA protein includes a Q63L mutation. In one or more embodiments, a mutant RhoA protein includes a G14V mutation. In one or more embodiments, a mutant RhoA protein includes a Y42C mutation.

[0055] In one or more embodiments, the mutant RhoA includes a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence similarity to human RhoA (SEQ ID NO: 1) and including at least one mutation. The mutation may include Y42C, G14V, Q63L, L57V, D59G, A61D, D76G, K18N, C16R, and / or A161P.

[0056] In one or more embodiments, the mutant RhoA includes a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, atleast 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence similarity to RhoA(Q63L) (SEQ ID NO:2).

[0057] In one or more embodiments, the mutant RhoA includes a sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% amino acid sequence similarity to RhoA(G14V) (SEQ ID NO:3).

[0058] In another aspect, the present disclosure relates to an engineered cell including a knockout of a protein associated with RhoA regulation. By knocking out a regulator of RhoA, an engineered cell may exhibit increased RhoA activity. In one or more embodiments, an engineered cell includes a knockout of human ARHGAP5, AHRGAP35, and / or AHRGAP19. While described herein in the context of a human gene knockout, it should be understood that similar targets may be knocked out in other cell types, such as murine cells.

[0059] In one or more embodiments, the engineered cell may include a therapeutic targeting construct. The therapeutic targeting construct may be, for example, a bispecific killer cell engager (BiKE), a trispecific killer cell engager (TriKE), or a chimeric antigen receptor (CAR). The therapeutic targeting construct may have any suitable target. Typically, the target is associated with solid tumor cells. In one or more embodiments, the therapeutic targeting construct is a CAR targeting mesothelin. The therapeutic targeting construct typically targets a tumor-associated antigen. In one or more embodiments, the therapeutic targeting construct targets HER2, PSMA, EGFR, CD19, AFP, AXL, B7-H3, CAIX, CD44v6, CD70, CD133, CD147, CD A, CEA, CDACAM5, Claudinl8.2, DLL3, EpCAM, FRa, GD2, Glypican-3, HLA-G, IL13-ra2, Ll-CAM (CD177), LMP-1, MAGE-A4, MUC1, MUC16, NKG2D, PD-L1, PSCA, PSMA, ROR1, TAG-72, CSPG4, or VEGFR2.

[0060] Methods of treating

[0061] In another aspect, the present disclosure relates to a method of treating a subject with an engineered cell. In one or more embodiments, a method of treating a subject includes administering to the subject the engineered cell described herein. In one or more embodiments, the subject is a mammal. In one or more embodiments, the subject is human. In one or moreembodiments, the subject is a farm or companion animal, such as a horse, a cow, a pig, a goat, a sheep, a chicken, a dog, a cat, a ferret, a rabbit, a guinea pig, or a chinchilla.

[0062] In one or more embodiments, the subject has cancer. Typically, the subject has a cancer characterized, at least in part, by the presence of one or more solid tumors. Examples of cancers having solid tumors suitable for treatment with methods of the present disclosure include pancreatic cancer, such as pancreatic ductal adenocarcinoma, lung cancer, breast cancer, colon cancer, bladder cancer, prostate cancer, skin cancer, and brain cancer. The methods of the present disclosure are typically useful in treatment of cancer having strong desmoplastic stromal reaction.

[0063] In one or more embodiments, the subject has a cancer comprising one or more fibrotic tumors. As is described herein, fibrotic tumors generally limit immune cell movement and sampling, such as T cell movement and sampling. The engineered cells of the present disclosure typically exhibit improved movement and sampling in a fibrotic environment such as a fibrotic tumor.

[0064] In one or more embodiments, the subject has a fibrotic state. The fibrotic state may be cancerous or non-cancerous. The fibrotic state may be, for example, liver fibrosis, pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), liver cirrhosis, or renal fibrosis. The fibrotic state may be or may result from a chronic disease such as a viral infection, environmental exposure, autoimmune condition, metabolic disorder, cancer, or age-related degeneration. Fibrotic state are typically characterized by increased deposition of the extracellular matrix, including fibrillar collagen, and may include scarring and tissue stiffening. Fibrosis may appear in numerous organs, including the lungs, liver, kidneys, heart, and skin.

[0065] As used herein, the terms “treat” or variations thereof refer to reducing, limiting progression, ameliorating, or resolving, to any extent, the symptoms or signs related to a condition. A “treatment” may be therapeutic or prophylactic. “Therapeutic” and variations thereof refer to a treatment that ameliorates one or more existing symptoms or clinical signs associated with a condition. “Prophylactic” and variations thereof refer to a treatment that limits, to any extent, the development and / or appearance of a symptom or clinical sign of a condition. Generally, a “therapeutic” treatment is initiated after the condition manifests in a subject, while “prophylactic” treatment is often initiated before a condition manifests in a subject.Treating a condition can be prophylactic or, alternatively, can be initiated after the subject exhibits one or more symptoms or clinical signs of the condition. Treatment that is prophylactic — e.g., initiated before a subject manifests a symptom or clinical sign of the condition — is referred to herein as treatment of a subject that is “at risk” of having the condition. As used herein, the term “at risk” refers to a subject that may or may not actually possess the described risk. Thus, for example, a subject “at risk” of a condition is a subject possessing one or more risk factors associated with the condition such as, for example, genetic predisposition, ancestry, age, sex, geographical location, lifestyle, or medical history. Treatment may also be continued after symptoms have resolved, for example to delay or reduce the likelihood of recurrence.

[0066] Accordingly, a composition can be administered before, during, or after the subject first exhibits a symptom or clinical sign of the condition. Treatment initiated before the subject first exhibits a symptom or clinical sign associated with the condition may result in decreasing the likelihood that the subject experiences clinical evidence of the condition compared to a subject to which the composition is not administered, decreasing the severity of symptoms and / or clinical signs of the condition, and / or completely resolving the condition. Treatment initiated after the subject first exhibits a symptom or clinical sign associated with the condition may result in decreasing the severity of symptoms and / or clinical signs of the condition compared to a subject to which the composition is not administered, and / or completely resolving the condition.

[0067] Thus, the method includes administering an effective amount of the composition to a subject having, or at risk of having, a particular condition. In this aspect, an “effective amount” is an amount effective to reduce, limit progression, ameliorate, or resolve, to any extent, a symptom or clinical sign related to the condition.

[0068] Structural similarity of two amino acid sequences can be determined by aligning the residues of the two sequences (for example, a candidate ACD and a reference cytidine deaminase described herein) to optimize the number of identical amino acids along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to optimize the number of identical amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. A candidate altered cytidine deaminase is the cytidine deaminase being compared to the reference cytidine deaminase. A candidateACD that has structural similarity with a reference cytidine deaminase and cytidine deaminase activity is an altered cytidine deaminase.

[0069] Unless modified as otherwise described herein, a pair-wise comparison analysis of amino acid sequences can be conducted, for instance, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Current Protocols in Molecular Biology, Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., supplemented through 2004). One example of an algorithm that is suitable for determining structural similarity is the BLAST® algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). The BLAST® algorithm can be used to calculate percent sequence identity and percent sequence similarity between two sequences. Software for performing BLAST® analyses is publicly available through the National Center for Biotechnology Information.

[0070] In the comparison of two amino acid sequences, structural similarity may be referred to by percent “identity” or may be referred to by percent “similarity.” “Identity” refers to the presence of identical amino acids. “Similarity” refers to the presence of not only identical amino acids but also the presence of conservative substitutions. Thus, in one embodiment the amino acid sequence of a cytidine deaminase protein having sequence similarity to a reference sequence may include conservative substitutions of amino acids present in that reference sequence.

[0071] A conservative substitution for an amino acid in a protein may be selected from other members of the class to which the amino acid belongs. For example, it is well-known in the art of protein biochemistry that an amino acid belonging to a grouping of amino acids having a particular size or characteristic (such as charge, hydrophobicity, or hydrophilicity) can be substituted for another amino acid without altering the activity of a protein, particularly in regions of the protein that are not directly associated with biological activity. For example, amino acids having a non-polar side chain include alanine, glycine, isoleucine, leucine,methionine, phenylalanine, proline, tryptophan, and valine; amino acids having a hydrophobic side chain include glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; amino acids having a polar side chain include arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, cysteine, tyrosine, and threonine; and amino acids having an uncharged side chain include glycine, serine, cysteine, asparagine, glutamine, tyrosine, and threonine.

[0072] In the preceding description and following Examples and claims, the term “and / or” means one or all of the listed elements or a combination of any two or more of the listed elements; the terms “comprises,” “comprising,” and variations thereof are to be construed as open ended — i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0073] As used herein, “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising” or the like are used in their open-ended inclusive sense, and generally mean “include, but not limited to,” “includes, but not limited to,” or “including, but not limited to.” Further, wherever embodiments are described herein with the language “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising” and the like, otherwise analogous embodiments described in terms of “consisting of’ and / or “consisting essentially of’ are also provided. The term “consisting of’ means including, and limited to, that which follows the phrase “consisting of.” That is, “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present. The term “consisting essentially of’ indicates that any elements listed after the phrase are included, and that other elements than those listed may be included provided that those elements do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements.

[0074] As used herein, the word “exemplary” means to serve as an illustrative example and should not be construed as preferred or advantageous over other embodiments.

[0075] As used herein, the terms “preferred” and “preferably” refer to embodiments of the invention that may afford certain benefits under certain circumstances. However, otherembodiments may also be preferred under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and is not intended to exclude other embodiments from the scope of the invention.

[0076] In the preceding description, particular embodiments may be described in isolation for clarity. Reference throughout this specification to “one embodiment,” “an embodiment,” “certain embodiments,” “one or more embodiments,” or “some embodiments,” etc., means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of such phrases in various places throughout this specification are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, features described in the context of one embodiment may be combined with features described in the context of a different embodiment except where the features are necessarily mutually exclusive.

[0077] In several places throughout the above description, guidance is provided through lists of examples, which examples can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

[0078] For any method disclosed herein that includes discrete steps, the steps may be performed in any feasible order. And, as appropriate, any combination of two or more steps may be performed simultaneously.

[0079] EXAMPLES

[0080] The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

[0081] Example 1- T Cell Migration is Restricted in the PDA Tumor Microenvironment To directly assess T cell movement in real-time, CD8+T cell motility in live ex vivo PDA tumor slices was characterized and compared to migration in a less complex 3D collagen gel matrix.Mouse T cell isolation, activation, and culture

[0082] Mouse cytotoxic CD8+T lymphocytes were extracted from 1045 + / + genetically engineered mice spleens using a CD8+T cell isolation kit (EASYSEP, STEMCELL Technologies Inc., Vancouver, Canada), following the manufacturer’s recommendation. Isolated CD8+T cells are cultured and activated using the Dynabeads Mouse T-Activator CD3 / CD28 (Thermo Fisher Scientific, Inc., Waltham, MA), following the manufacturer’s recommendation. If frozen T cell were used, the cells were thawed in a 37 °C water bath for two to three minutes and washed in 10 mL fresh pre-warmed Immunocult media to remove excessive DMSO in the medium. Thawed T cells are allowed to recover in fresh Immunocult medium supplemented with 30 U / ml IL-2 (STEMCELL TM Technologies Inc., Vancouver, Canada) for at least 24 hours before subsequent experiments.

[0083] To evaluate T cell motility in the naive PDA tumor microenvironment, aCD3 / aCD28 bead activated mouse CD8+T cells isolated from mouse spleen were plated onto live autochthonous PDA tumor slices harvested from genetically engineered KPC mice. T cells were given one hour to infdtrate the tumor slice, after which any remaining cells outside the tissue were washed off. Migration of the infiltrated T cells was visualized using two-photon microscopy, and time-lapse images were captured to analyze movement patterns over time.

[0084] Within the live PDA tumor slice, which presents a dense fibrillary collagen network and a complex molecular landscape, T cell movement was highly restricted (FIG. 1 A). In contrast, T cells migrating in a simpler, less dense 3D collagen gel exhibited significantly higher motility (FIG. 1A). Even after eight hours in the tumor slice, T cells covered significantly less distance than those in the collagen gel in just one hour, highlighting the profound limitations imposed by the PDA microenvironment. Quantitative analysis confirmed a major reduction in motility coefficient (FIG. 2A), calculated using the persistent random walk model (PRWM), total displacement (FIG. 2A), and track confinement ratio (FIG. 2A) in tumor slices compared to the collagen gel.

[0085] To further quantify the extent of T cell restriction in the PDA tumor microenvironment, the total area covered by T cells within the tumor slice was analyzed and compared to the collagen gel. Over an eight-hour period, T cells in the tumor slice covered less than 5% of the total field of view (FOV), whereas T cells in the collagen gel covered approximately 10% of theFOV in just 1 hour. This demonstrates that despite a much longer observation period, T cells in the tumor slice remained largely confined to small, localized regions, while those in the collagen gel were able to spread more efficiently and cover a larger area in a fraction of the time (FIG. 2B). In addition to reduced total area coverage, the distribution of T cells within the PDA tumor slices was highly uneven, with large portions of the tumor remaining completely devoid of T cells. In contrast, T cells in the collagen gel exhibited a more uniform distribution, indicating that they were able to freely migrate and explore their environment without encountering significant physical constraints (FIG. 2C). The presence of extensive T cell-free zones in the PDA tumor slices suggests that tumor-associated barriers not only restrict movement but may also create exclusion zones where T cells are unable to penetrate, further limiting effective immune surveillance within the tumor microenvironment.

[0086] Example 2- Generating RhoA Q63L engineered T cells Here, T cells having enhanced RhoA activity were generated and tested to determine whether increased RhoA activity in T cells improved their infiltration and migration within tumors. The RhoA Q63L mutation, which replaces glutamine with leucine at position 63, was identified as a constitutively active form of RhoA by preventing GTP hydrolysis, thereby leading to persistent RhoA activation.

[0087] Human T cell culture

[0088] Human T cells were isolated from healthy human donor and stimulated with anti-human CD3 / CD28 beads in Optimizer human T cell expansion medium supplemented with 30 U / mL of human IL-2, IL-7, and IL-15. , and transduced with lentivirus at MOI=20 on day 2. The transduced T cells were purified on day 4 with PE-CD34 QBEND / 10 antibody (Thermo Fisher Scientific, Inc., Waltham, MA) and a PE-positive selection kit (EASYSEP, STEMCELL Technologies, Inc., Vancouver, Canada). Cell purity was examined with flow cytometry. High purity T cells (purity>95%) were transferred to 24-well G-REX culture vessels to expand for three days.

[0089] Generating human and mouse RhoA Q63L mutant CD8+T cellsTo investigate the effects of RhoA Q63L mutant on T cell migration, human CD8+ T cells were transduced with a lentivirus encoding RhoA Q63L mutant and RQR8, under MND promoter, which initiates strong downstream gene expression in T cells (FIG. 3). RQR8 is an epitope-based marker integrates CD34 and CD20, allowing positive selection of the successfully transduced cells, assuring high purity.

[0090] To prepare lentivirus encoding human RhoA Q63L and RQR8 for purification, the human amino acid codon optimized sequences of RhoA Q63L and RQR8 were linked with a T2A sequence and inserted to a pLV lentivirus backbone and driven by a synthetic viral promoter, MND. Vectors encoding overexpression RhoA-T2A-RQR8, and T2A-RQR8 were designed as controls. For generating the mouse RhoA Q63L mutant T cells, cells were transduced with retrovirus constructs similar to the human constructs. Briefly, mouse amino acid codon optimized sequences of RhoA Q63L and RQR8 were linked with a T2A sequence and driven by the murine stem cell virus (MSCV) promoter. Both human and mouse RhoA Q63L and control vectors and the respective lentiviruses and retroviruses were prepared by VectorBuilder Inc. (Chicago, IL).

[0091] To assess potential genetic variation, three batches of the RhoA Q63L mutant T cells and the controls from three donors were prepared. After purification, transduced T cell purity was assessed using flow cytometer, and the result showed over 97% purity (FIG. 3C). RhoA-GTP expression in the purified T cells was analyzed by RhoA-GTP pulldown and Western blot assays. The RhoA Q63L mutant T cells express high level of RhoA-GTP and total RhoA, over 51 times and 11 times higher than the respective RQR8 control (FIG. 4A). The WT RhoA overexpression control T cells also express higher level of RhoA-GTP and total RhoA protein, over 22 times and 35 times higher than the respective RQR8 control. To control for the inherently lentivirus-associated immune responses and RhoA activation in T cells, negative control EGFP lentivirus and RhoA activators, (LPA and Rail) were tested in parallel. The RhoA and RhoA-GTP level in basal (PBS), EGFP virus basel (EGFP virus+PBS) were very similar to the RQR8 control, but more than 50 times lower than RhoA Q63L, even after activated by LPA or Rail. These data suggested that the basal RhoA and RhoA-GTP levels in human T cells are very low relative to RhoA overexpression T cells

[0092] ImmunofluorescenceThe distribution of RhoA-GTP was further characterized using immunofluorescence. T cells were fixed with 1% paraformaldehyde for 10 minutes and washed with PBS once. The fixed T cells were resuspended on deionized water and transferred to positively charged glass slides. The slides were air dried in a running cell culture hood, typically, in 10 to 20 minutes, to attach T cells on slides. The T cells on the slides were subsequently permeabilized with 0.3% Triton X-100 in PBS for 10 minutes, and blocked with 1% FBS, 0.5% BSA for 60 minutes in room temperature. To examine total RhoA and RhoA-GTP, 1:50 rabbit anti -total RhoA (Novus Bio, Centennial, CO) and 1:100 mouse anti-RhoA-GTP (NewEast Biosciences, King of Prussia, PA) diluted in the blocking buffer were incubated with the T cells at 4°C overnight. The slides were them washed three times with PBST buffer, each for five minutes, followed by the incubation of Alexa Fluor568-conjugated donkey-anti-rabbit IgG (1 : 100) and Alexa Fluor488-conjugated donkey anti-mouse IgG (1 : 100, Carlsbad, CA) at room temperature for 60 minutes. The slides were washed three times with PBST buffer and mounted with VectorShield mounting media (Vector Laboratories, Newark, CA), and examined with an Olympus fluorescence microscope (Olympus America, Bartlett, TN).

[0093] RhoA-GTP proteins are mainly distributed near cytoplasmic membrane, while total RhoA proteins are in cytoplasm (FIG. 4B). RhoA Q63L and control T cells were analyzed one day and three days after transduction. On day 1, RhoA-GTP levels were increased in all transduced T cells (FIG. 4). On day 5, the total fluorescence intensity of RhoA-GTP or RhoA in Rho Q63L was significantly higher than the RQR8 control

[0094] RhoA-GTP pulldown and Western blots:

[0095] To examine RhoA-GTP induced by RhoA Q63L constitutional mutant, T cells were harvested for RhoA-GTP pulldown assay with RBD beads following manufacturer’s instructions (Cytoskeleton Inc., Denver, CO). RhoA-GTP and total RhoA were examined by Western blots with rabbit anti-human RhoA (1:500, Cell Signaling, Danvers, MA) and mouse anti-P-actin (1:1000, GeneScript, Piscataway NJ) antibodies, followed by secondary antibodies of IR680-conjugated donkey anti-rabbit IgG (1:2500) and IR800-conjugated donkey anti-mouse IgG (1:2500, LI-COR, Nebraska, USA) .Western blotting supported the finding that total RhoA-GTP and RhoA were increased in RhoA Q63L mutant T cells (FIG. 4A).To ensure the Q63L mutation did not affect T cell proliferation or viability, T cell expansion in culture was monitored over seven days (FIG. 5). The RhoA Q63L modified T cells and the control cells, showed no significant differences in cell number and viability, indicating the Q63L mutation did not impair cell cycle progression or survival. Despite showing a similar proliferation rate, RhoA Q63L modified T cells displayed distinct morphological changes in 3D matrices. Two-photon imaging of the live T cells in collagen gel revealed that the Q63L modified T cells displayed a more elongated cell shape and increased cell size compared to the unmodified cells (FIG. 5). This observation is consistent with cell displaying an ameboid migration pattern, characterized by enhanced cellular cortical contractility and cytoskeletal remodeling.

[0096] Example 3- RhoA Q63L mutation enhances both human and mouse

[0097] T cell migration in different substrates

[0098] To assess the impact of constitutively active RhoA (Q63L) on T cell motility, migration was first analyzed migration in a 3D collagen gel system This system serves as a baseline assay for intrinsic migratory potential in the absence of chemotactic cues.

[0099] T cell migration assay

[0100] Human CD8+T cells were prepared as described in Example 2. To assess migration, CD8+T cells were labeled with 2 pM CELLTRACKER Green (Thermo Fisher Scientific, Inc., Waltham, MA) and seeded onto either 3D collagen matrices or PDA tumor slices derived from KPC or KPCT mice. Collagen gels were prepared from high-concentration rat tail collagen type I, neutralized with an equal volume of HEPES buffer, and allowed to polymerize before cell seeding. KPC tumor slices were stained with 5 pM CELLTRACKER Red CMTPX, while KPCT slices required no staining due to endogenous tdTomato expression. Following a one-hour incubation at 37 °C, collagen gels or tumor slices were rinsed with warm L-15 medium containing 1% FBS to remove non-infiltrating T cells and transferred to 35 -mm imaging dishes. A tissue harp was used to stabilize the gels or slices. For live-cell imaging, 5 mL of L-15 medium supplemented with 10% FBS, 1% penicillin / streptomycin, 5 pg / mL PLASMOCIN (Invivogen, Toulouse, France), and 10 pg / mL STI was added. The imaging chamber was maintained at7 °C. T cell migration was recorded at up to two regions of interest per sample, capturing 100 pm z-stacks (5 pm step size) at one-minute intervals for up to eight hours.

[0101] Migration analysis

[0102] Briefly, timelapse images of the CD8+T cells migration on 3D collagen or KPC / KPCT tumor slices are post-proceeded in Fiji. Stage drifts are corrected using the 3D correction plugin in Fiji using the SHG channel for registration. T cell movements can be tracked using the Trackmate plugin in Fiji, where dynamic threshold and filters can be used to exclude erroneous tracks that might be generated by imaging artifacts or the tracking program (Tinevez et al., 2017). The post-processed cell tracking data are then analyzed by fitting to a persistent random walk model using overlapping intervals in the MATLAB model as previously described (Ray et al., 2017). Briefly, the cell’s mean squared displacement (MSD) over time interval it is taken from the average of all squared displacements such that: f =ni — — i + 1, where

[0103]

[0104] i is the number of overlapping time intervals of duration tt, and N is the total number of time intervals. The mathematical representation of the persistent random walk model is the following: MSD = 2S2P[t — P(1 — e“p], where S is the migration speed, and P is the persistent time.

[0105] 52p

[0106] The motility coefficient can be written as such that: p = — , where na is the dimensionality ofnd

[0107] the random walk. For this study, the motility, speed, and persistence times for x, y, and z directions were obtained by fitting the model separately into three orthogonal directions; thus, n is one for each case. The total speed of each cell can be calculated by taking the square root of the squared sum of speed in each of the three directions, x, y, and z. The equation can be written as such that: S =

[0108]

[0109] + Sy + S? . The total motility of each cell can be obtained by adding the motility of each direction and can be written as such that: p = px+ py+ pz.

[0110] Human CD8+T cells expressing RhoA Q63L exhibited significantly increased motility compared to control cells, as measured by a two-fold increase in motility coefficient and a higher track confinement ratio (arbitrary units from 0 to 1, where 1 indicates a straight trajectory). RhoA Q63L-modified T cells also covered a larger area over time, consistent with enhanced intrinsic migration (FIG. 6).Mouse CD8+T cells transduced with RhoA Q63L retrovirus were prepared as described in Example 2 and analyzed for proliferation, viability, and morphology. Mouse CD8+RhoA Q63L T cells displayed similar proliferation rates and viability compared to controls, and exhibited a more elongated morphology and enlarged cell size consistent with the human RhoA modified T cells. In 3D collagen matrices, RhoA Q63L-modified mouse T cells also demonstrated significantly greater motility relative to control T cells.

[0111] Live PDA tumor slice preparation

[0112] To determine whether the enhanced migration persists in a physiologically relevant tumor environment, T cell behavior in live tumor slices derived from KPC / KPCT pancreatic tumors was examined. Fresh pancreatic tumor tissue harvested from KPC or KPCT genetically engineered mice was kept on ice in 1 x PBS with 10 pg / ml STI for support before slicing using a tissue vibratome (Campden Instruments, London, UK). The harvested tumor is superglued to the vibratome cutting stage with 1.5% agarose gel as support. The stage is filled with ice-cold 1 xPBS for tumor slicing, and tumor tissue is sectioned at a 350-pm thickness with a vibratome speed of 0.3 mm / s and frequency of 8mm. Sliced tumors are placed in sterile ice-cold 1 *PBS with soybean trypsin inhibitor (STI) for transport. Tumor slices are then carefully transferred and cultured in a six-well, or 12-well tissue culture plate with an organotypic tissue culture insert (Millipore Sigma, US) coated with 3 mg / ml of rat tail collagen type 1 neutralized with ImM HEPE in 2 PBS at a 1 : 1 ratio and completed with 1 x PBS. Multiple slices are placed flat on 0.4 pm, 30 mm diameter cell culture inserts, while a single tumor slice can be placed on 0.4 pm, 12 mm diameter cell culture inserts. Tumor slices were cultured in prewarmed RPMI 1640 supplemented with 10% FBS, 1% penicillin and streptomycin (P / S), 5 pg / mL PLASMOCIN (Invivogen, Toulouse, France), and 10 pg / ml of STI at 37 °C in a 5% CO2 humidified incubator. The tissue culture medium is changed daily, and the pancreatic tumor slices can be cultured for up to 6 days while preserving tissue integrity and cell viability.

[0113] Within the ex vivo tumor slices, RhoA Q63L-modified T cells showed significantly increased velocity and directional persistence compared to controls (FIG. 7). Furthermore, quantification of the area sampled / covered by the infiltration T cells over 1 hour showed that the Q63L modified T cells were able to patrol over 50% of the FOV, whereases the control T cells covered less than 10%, resulting in multiple T-cell free regions. These findings indicate thatRhoA activation promotes T cell migration not only in simplified 3D matrices but also within the structurally dense and immunosuppressive PDA tumor microenvironment. Additionally, RhoA Q63L modified T cells demonstrated more effective tissue surveillance and spatial distribution, suggesting an increased capacity to explore and patrol the intratumoral space.

[0114] Example 4 - RhoA Q63L enhances T cell cortical tension, metabolism, and functional differentiation

[0115] The effect of RhoA Q63L modification on cell metabolism was characterized. Using fluorescence lifetime imaging microscopy (FLIM), the nicotinamide adenine dinucleotide (NAD(P)H) fluorescence lifetimes of the Q63L modified T cells and unmodified T cells with and without aCD3 / aCD28 T cell activator antibody were measured.

[0116] Briefly, T cells were cultured overnight with or without ImmunoCult human CD3 / CD28 T cell activator antibodies (StemCell, Cat. #10971). One million cells of each type were then added to 3 mg / mL collagen gels in 24 well plates and allowed to infiltrate for one hour. The collagen gel was removed from the well, rinsed, and placed in a 35-mm dish under a tissue harp in L15 media for imaging. For each gel, 4-6 Z stacks in 5-pm steps were collected. (The excitation source is an ultrafast (12.5 ns pulse) titanium: sapphire laser (Mai Tai) tuned to 750 nm. NAD(P)H emission was collected through a 460 / 50 bandpass filter into a GaAsP photon counting PMT From the PMT, photon data were time tagged using SPC-150 photon counting electronics (Becker & Hickl GmBH).

[0117] Each lifetime image was imported to SPCImage 8.9 (Becker & Hickl GmBH) and the fluorescence lifetime was deconvolved from the instrument response function using a bin of 16 pixels (4><4) and fit to a two component exponential decay model corresponding to the short and long lifetime components of NAD(P)H. al is the fractional contribution of the short lifetime component, was exported as text images, and used as an indicator of T cell metabolism and T cell activation as previously described. Using the Fiji package of Imaged, NAD(P)H intensity images were thresholded to include cytoplasm but omit the dim nucleus and background and converted to binary. Binary images were divided by 255 so included pixels equal 1 and excluded pixels equal 0 and then multiplied by the corresponding al images, al values from all remaining pixels were averaged and the averages compared using an ordinary one-way ANOVA with Tukey's multiple comparisons test in GraphPad Prism 10.4.1.These results showed that the Q63L modified T cells displayed a higher percentage of al (FIG. 8A, FIG. 8B).The fraction of free co-enzyme that contribute to the short lifetime component, indicating a shift in cellular metabolism toward glycolysis, a state more often associated with T cell activation and proliferation. aCD3 / aCD28 T cell activator antibody treated Q63L modified T cells have the highest percentage of NAD(P)H alpha 1, follow by Q63L modified T cell without aCD3 / aCD28 T cell activator antibody. In the control group, the aCD3 / aCD28 activated T cells also showed significantly increased alpha 1 percentage. There is no statistical significance between the activated control T cell and non-activated Q63L modified T cell group, suggesting an increase in the baseline metabolism rate for the Q63L modified T cells.

[0118] Cell migration is a dynamic process that is regulated through cell membrane tension. RhoA regulates cell migration through actin-myosin contractility. Persistent RhoA activation resulting from the Q63L mutation may change T cell biomechanic properties. The Flipper- TR fluorescent cell membrane tension probe was used to measure cell membrane tension through FLIM. The Q63L modified T cells displayed increased cell cortical membrane tension compared to the control group (FIG. 8). The increased cell cortical membrane tension is consistent with the fast ameboid migratory phenotype, characterized by rapidly changing shape and relying less on strong adhesion to the surrounding environment.

[0119] Flow Cytometry to assess T cell differentiation, activation, and exhaustion

[0120] To further investigate the effects of RhoA Q63L on T cell function, T cell activation, differentiation, and exhaustion status were analyzed using multiparameter flow cytometry.

[0121] Isolated human T cells were stained using standard procedures with the following panel and analyzed by flow cytometry using a BD FACSymphony A3 Cell Analyzer (Becton, Dickinson and Company [BD]) at the University of Minnesota - Twin Cities, University Flow Cytometry Resource: Live / Dead Ghost 780 (Cytek / TONBO, Cat. # 13-0865-T100), CD45-BUV661 (BD, Cat. # 705178), CD3-BUV396 (BD, Cat. # 563548), CD4-APC-R700 (BD, Cat. # 565995), CD8-RB613 (BD, Cat. # 571090), CD45RA-RB705 (BD, Cat. # 757395), CCR7-BV421 (BD, Cat. # 566744), CD27-RY610 (BD, Cat. # 571334), CD28-BV711 (BD, Cat. # 563131), CD62L-BV650 (BD, Cat. # 563808), CD25-PE-Cy7 (BD, Cat. # 560920), CD127-BUV496 (BD, Cat. # 749984), CD103-FITC (BD, Cat. # 567677), PD1-BV605 (BD, Cat. # 563245), LAG3-BV51O(BD, Cat. # 746609), TCF1-AF647 (BD, Cat. # 566693), and CD69-BUV737 (BD, Cat. # 612818). Gating for T cell differentiation was done as previously described.

[0122] Compared to unmodified controls, RhoA Q63L-modified T cells exhibited a higher percentage of CD8+T cells and effector T cell subsets, suggesting that these cells are better at maintaining their cytotoxic and effector functions. Given this shift toward an enhanced effector phenotype, the extent to which RhoA Q63L mutation alters the differentiation stages of CD8+T cells was examined. CD8+T cell differentiation can be ordered from naive (Tn) cells to central memory (Tcm), effector memory (Tern), and terminally differentiated effector (E) cells, with each stage characterized by distinct cell surface marker expression. Using established gating strategies based on CD45RA, CCR7, CD27, and CD28 expression, RhoA Q63L-modified T cells exhibited a more differentiated subsets compared to the unmodified controls. Most of the Q63L-expressing T cells were found in the Tem3 (60%) and E (15%) stages, whereas unmodified T cells had a significantly lower percentage of Tem3 cells (<40%) and effector cells (<20%) (FIG.

[0123] 10). Additionally, the control group included a higher percentage of naive T cells. Taken together, RhoA Q63L mutation in T cells promotes a shift toward functionally mature and specialized effector subsets. Highly differentiated T cells, particularly Tem3 and E subsets, are often associated with increased cytotoxic phenotype. Further analysis into T cell exhaustion marker PD-1 and LAG-3 expression revealed that RhoA Q63L-modified T cells did not exhibit signs of exhaustion. Instead, these cells maintained a functional, cytotoxic phenotype with strong effector potential, distinguishing them from exhausted T cell populations typically observed in TME. These results suggest that, in addition to enhancing T cell migration, RhoA Q63L modification drives differentiation toward a more functionally potent effector state while preventing exhaustion-associated dysfunction. This unique combination of enhanced mobility, differentiation, and resistance to exhaustion may provide a therapeutic advantage in improving the persistence and effectiveness of engineered T cells in solid tumors.

[0124] Example 5 - Incorporating mesothelin-CAR into RhoA Q63L T cells led to increased T cell-cancer cell interaction events

[0125] Finally, RhoA Q63L modified T cells were characterized in a therapeutic setting by preparing CAR T cells. Mesothelin, a surface antigen that is normally low expressed in normal tissue but highly expressed by PDA cancer cells, is a promising neoantigen for CAR T cell targetfor PDA treatment. A mesothelin-CAR was designed and incorporated into human CD8+ T cells with (mesoCAR) and without the RhoA Q63L (mesoCAR Q63L) mutation (FIG. 11 A). Western blot and RhoA protein pulldown assay confirmed the mesoCAR Q63L T cells have increased total RhoA total protein as well as increased RhoA-GTP (FIG. 1 IB), consistent with previous results. Time-lapse imaging of the mesoCAR T cells infiltrated into 3D collagen matrices showed enhanced migration capacity of the Q63L modified T cells evidenced by almost two-fold increase in motility coefficient, speed, displacement, total distance traveled, and track confinement ratio.

[0126] To investigate the therapeutic potential of the mesoCAR Q63L T cells, the 2D killing of the cells by co-culture the mesoCAR T cells with AsPCl PDA cancer cell line was examined in a 96-well plate with a 1:1, 1:5, 1:10, or 1:20 cancer cell to T cell ratio for 48 hours. Cancer cells cultured without T cells were used as a baseline and the percent survival for each of the coculture groups to the control was calculated. Equal number of tumor cells were plated in each well and the corresponding ratio of T cells to tumor was added to assess T cell killing. The cells were cocultured for 48 hours before assaying T cell killing efficacy using flow cytometer (BD Biosciences, NI). T cells and tumor cells were selected based on size and complexity using the FSC / SSC plot. Tumor cells cultured without T cells were used as a baseline and the percent survival for each of the coculture groups was calculated.

[0127] MesoCAR T cells with and without Q63L modification exhibited similar levels of cancer cell killing. Both groups displayed a trend in increased cancer cell killing as the ratio of cancer cell to T cell increases, suggesting the Q63L modification does not impair CAR-mediated cytotoxicity in a 2D environment.

[0128] 3D infiltration assay

[0129] While 2D assays provide a directly method to assess T cell cytotoxicity, they do not mimic the complex, collagen-dense 3D environment that T cells must infiltrate and navigate within solid tumors. Thus, to better capture these interactions, AsPCl PDA cancer cells were stained and embedded in 3 mg / mL of collagen gels, plated mesoCAR T cells onto the top of the gels and allowed 90 minutes to infiltrate before performing time-lapse imaging for two hours.

[0130] 500K AsPCl cells (ATCC, VA) were stained with 5 pM CELLTRACKER Red (Thermo Fisher Scientific, Inc., Waltham, MA) and mixed in 3 mg / mL of 3D collagen gel. The cellcollagen mixtures were then transferred to a 24 well plate and were allowed to polymerize overnight in 37 °C incubator. CD8+T cells labeled with 2 pM CELL TRACKER Green were then plated on top of the collagen matrix and incubated for one hour for T cells to infdtrate. Any T cells remaining outside of the collagen gel after incubation was washed off. T cell, AsPC cell, and collagen were virtualized in using multiphoton microscope and second harmonic generation and imaged for 90 minutes with a 100 pm z section, one-minute interval. T cell: carcinoma interaction frequency was then analyzed using PhenoTrack, a component of the TME-CART algorithm suite, that uses T cell morphology, velocity, and physical proximity with carcinoma cells to identify the phenotypic behavior of cells. Taking inputs of T cell tracks and T cell morphology over time from TrackMate in FIJI, PhenoTrack examines T cell velocity, circularity, the change in cell circularity, and the distance to cancer cells at each frame for each T cell. Based on tunable thresholds for each parameter, PhenoTrack assigns a plausible status (migration, stalling, interaction) to each cell at each time point.

[0131] T cell migration and morphology changes were tracked using the TrackMate plugin in ImageJ. Using the location of T cells and cancer cells, and T cell behavior parameters, the number of T celkcancer cell interaction events per T cell was calculated. A T celkcancer cell interaction event is defined using the following criteria: (1) physical proximity, T cell needs to be with 20 pm of a cancer cell; (2) reduced cell velocity, with a threshold below 11.6 pm / min.; (3) persistent morphology changes, where T cell circularity remined below 0.9 with at least 0.1 change between each frame; and (4) sustained interaction, requiring all above criteria to be met for three consecutive frames.

[0132] On average, the mesoCAR control group had two interaction events per T cells, whereas the mesoCAR Q63L modified group had four interaction events with cancer cells per T cells, a two-fold increase compared to the control group.

[0133] Interesting, despite its superior motility in 3D collagens without AsPC l cells, the motility coefficient of mesoCAR Q63L T cells were lower than that of the mesoCAR control T cells in this setting. The reduction in overall motility may be a result of increased cancer cell interaction. When not interacting with cancer cells, Q63L-expressing T cells likely migrated faster, enabling them to locate targets more effectively. This faster search time results in a higher frequency of interactions, ultimately leading to a decrease in net motility due to prolonged engagement with cancer cells. When the area covered by T cells over the entire imaging period was examined, thearea covered by mesoCAR Q63L was more concentrated around cancer cells compared to the control group, indicated by bright yellow spots surrounding cancer cells.

[0134] To further test this hypothesis, the experiment was repeated using T cells without mesoCAR modification. Q63L modified T cells maintained their superior motility coefficient compared to the control, confirming that the motility reduction in the mesoCAR Q63L T cells was specific to cancer cell interaction rather than an intrinsic change in migration potential.

[0135] The complete disclosure of all patents, patent applications, and publications, and electronically available material (including, for instance, nucleotide sequence submissions in, e.g., GenBank and RefSeq, and amino acid sequence submissions in, e.g., SwissProt, PIR, PRF, PDB, and translations from annotated coding regions in GenBank and RefSeq) cited herein are incorporated by reference in their entirety. In the event that any inconsistency exists between the disclosure of the present application and the disclosure(s) of any document incorporated herein by reference, the disclosure of the present application shall govern. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

[0136] Unless otherwise indicated, all numbers expressing quantities of components, molecular weights, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0137] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherentlycontain a range necessarily resulting from the standard deviation found in their respective testing measurements.

[0138] All headings are for the convenience of the reader and should not be used to limit the meaning of the text that follows the heading, unless so specified.

[0139] SEQUENCE LISTING FREE TEXT

[0140] SEQ ID NO:1 - WT RhoAMAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ ARRGKKKSGC LVL

[0141] SEQ IDNO:2 - RhoA Q63L

[0142] MAAIRKKLVI VGDGACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT AGLEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ ARRGKKKSGC LVL

[0143] SEQ ID NOG - RhoA G14V

[0144] MA IRKKLVI VGDVACGKTC LLIVFSKDQF PEVYVPTVFE NYVADIEVDG KQVELALWDT AGQEDYDRLR PLSYPDTDVI LMCFSIDSPD SLENIPEKWT PEVKHFCPNV PIILVGNKKD LRNDEHTRRE LAKMKQEPVK PEEGRDMANR IGAFGYMECS AKTKDGVREV FEMATRAALQ ARRGKKKSGC LVL

Claims

What is claimed is:

1. An engineered immune cell comprising increased RhoA activity.

2. The engineered immune cell of claim 1, wherein the engineered immune cell comprises a mutant RhoA protein.

3. The engineered immune cell of claim 2, wherein the mutant RhoA protein comprises a constitutively activating mutation.

4. The engineered immune cell of any preceding claim, wherein the mutant RhoA protein comprises an amino acid sequence comprising a Y42C, G14V, Q63L, L57V, D59G, A61D, D76G, K18N, C16R, or A161P mutation.

5. The engineered immune cell of claim 4, wherein the mutant RhoA protein comprises a Q63L mutation.

6. The engineered immune cell of claim 4, wherein the mutant RhoA protein comprises a G14V mutation.

7. The engineered immune cell of claim 1, wherein the engineered immune cell comprises a protein having at least 70% sequence identity to SEQ ID NO:1 and a mutation at a position equivalent to Y42C, G14V, Q63L, L57V, D59G, A61D, D76G, K18N, C16R, or A161P.

8. The engineered immune cell of claim 1, wherein the engineered immune cell comprises a protein having at least 70% identity to SEQ ID NO:2.

9. The engineered immune cell of any preceding claim, wherein the cell is a human cell.

10. The engineered immune cell of any preceding claim, wherein the cell exhibits increased motility relative to a comparable unmodified cell.

11. The engineered immune cell of any preceding claim, wherein the cell exhibits increased solid tumor infiltration relative to a comparable unmodified cell.

12. The engineered immune cell of any preceding claim, wherein the cell is a T cell or an NK cell.

13. The engineered immune cell of any preceding claim, wherein the engineered immune cell comprises a chimeric antigen receptor (CAR), an engineered TCR, a targeting antibody, a bispecific killer cell engager (BiKE), or a trispecific killer cell engager (TriKE).

14. A method of treating a subject comprising administering the engineered cell of any preceding claim to the subject.

15. The method of claim 14, wherein the subject has cancer.

16. The method of claim 14 or 15, wherein the subject has one or more solid tumors.

17. The method of claim 14, wherein the subject has a fibrotic state.

18. The method of claim 17, wherein the non-cancerous fibrotic state comprises fibrosis of the lungs, liver, kidneys, heart, skin, or a combination thereof.

19. The method of claim 17, wherein the fibrotic state comprises liver fibrosis, pulmonary fibrosis, liver cirrhosis, or renal fibrosis.

20. The method of any preceding claim, wherein the subject is a human.